The Weekly Summary

Benghazi1May 6th – May 12th  

In general news, a study showed that environmental levels of CO2 are the highest in human history. The investigation into whether Hillary Clinton and the State Department covered up the death of the American ambassador in Benghazi, Libya, picked up momentum. New Jersey Governor Christie received a Lap-Band procedure for his obesity, and Iron Man 3 earned $700 Million in the box office, worldwide.

In healthcare business news, Actavis (ACT) might acquire Warner Chilcott (WCRX), following the failed attempt to merge with Valeant (VRX).  Eli Lilly’s (LLY) CEO underwent CABG surgery. The WebMD CEO announced his departure after only a year. Lastly, struggling Vivus (VVUS) announced plans to possibly partner with a Big Pharma to market weight loss drug Qsymia.

On the data front, LLY’s lymphoma drug, enzastaurin, failed. Also, Baxter’s (BAX) Alzheimer’s drug, Gammagard, failed.

From the FDA, AbbVie (ABBV) was the latest to receive Breakthrough status, and also for an HCV drug regimen. Recall, BMY received breakthrough for its HCV regimen last week. GlaxoSmithKline (GSK) received approval for COPD drug Breo Ellipta. Medtronic (MDT) had a new ICD approved. Lastly, Impax (IPXL) and Actavis received approval to make a generic version of Endo’s (ENDP) Opana opioid pain pill.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.